Science & Research
GeoVax Advances in Vaccine Development and Immunotherapy with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy pipeline, including favorable regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
American Heart Association Expands Initiative to Combat Cardiovascular-Kidney-Metabolic Syndrome Across 15 U.S. Regions
The American Heart Association's expansion of its Cardiovascular-Kidney-Metabolic Health Initiative to 15 U.S. regions aims to address the interconnected conditions leading to heart disease and stroke, marking a significant step in public health intervention.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Study Reveals Shifts in Child Physical Abuse Patterns During COVID-19 Pandemic
A recent study highlights that while the incidence of child physical abuse remained stable during the COVID-19 pandemic, there was a significant decline in severe head injuries, suggesting changes in abuse detection or reporting.
Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
Soligenix Inc. is developing SGX945, a promising treatment for Behçet’s disease, addressing the critical need for more effective therapies for this rare condition.
Clene Inc. Advances Neurodegenerative Disease Treatment with FDA-Backed Biomarker Analysis
Clene Inc. is set to initiate neurofilament biomarker analyses for its drug CNM-Au8 in ALS patients, marking a significant step towards innovative treatments for neurodegenerative diseases.
Humans Outperform AI in Math Olympiad, Yet AI Shows Significant Progress
Human participants surpassed AI systems from OpenAI and Google at the International Mathematical Olympiad, though AI achieved gold-medal scores for the first time, indicating rapid advancement.
Nobel Laureate Prof. Pierre Agostini on the Revolutionary Impact of Attosecond Science
Prof. Pierre Agostini discusses the groundbreaking implications of attosecond pulses in physics and beyond, highlighting their role in advancing our understanding of electron dynamics and potential applications in various fields.
Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promise in reducing the condition's severity and duration in cancer patients.
Seismic Imaging and Academic Studies Bolster Montauban's Potential as Broken Hill-Type Deposit
ESGold Corp.'s recent seismic imaging and academic research underscore the Montauban Gold-Silver Project's resemblance to the prolific Broken Hill deposit, highlighting its district-scale potential and advancing exploration strategies.
Aditxt Inc. Subsidiary Pearsanta Advances in DoD-Funded Ovarian Cancer Diagnostic Study
Aditxt Inc.'s subsidiary Pearsanta moves forward in a Department of Defense-funded study for early ovarian cancer detection, highlighting the potential impact on women's health diagnostics.
Aston Bay Holdings Reports Promising Copper Intercepts at Storm Project in Nunavut
Aston Bay Holdings Ltd. announces significant copper sulfide mineralization findings at its Storm Project in Nunavut, indicating potential for resource expansion and project advancement.
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment
The European Medicines Agency grants Orphan Designation to Candel Therapeutics' CAN-2409, highlighting its potential to address the significant unmet medical need in pancreatic cancer treatment across Europe.
GeoVax Shifts Gedeptin® Strategy to Neoadjuvant Combination Trial After KEYNOTE-689 Success
GeoVax Labs, Inc. announces a strategic pivot in its Gedeptin® clinical development program towards a neoadjuvant therapy combination with pembrolizumab for head and neck squamous cell carcinoma, following promising KEYNOTE-689 Phase 3 trial results.
Texas Mineral Resources Corp. Reports Positive Drilling Results in New Mexico's Black Hawk Mining District
Texas Mineral Resources Corp. announces encouraging preliminary drilling results at the Alhambra mine, indicating the potential for silver and sulfide vein discoveries in New Mexico's Black Hawk Mining District.
New Book Sheds Light on Gut Health's Role in Chronic Conditions
A new book by Dr. Kristin Kidgell and Ruth Brooks explores the connection between gut health and chronic illnesses, offering a science-backed approach to healing.
Community Health Centers Expand Screening for Cardiovascular Disease Marker Lp(a)
The American Heart Association's initiative to screen for lipoprotein(a) in community health centers aims to reduce cardiovascular disease risk by identifying inherited risk factors early.
Donna White to Spotlight Hormone Health at South Florida Event Following FDA Roundtable
Donna White, a leading expert in bioidentical hormone replacement therapy, will address the future of hormone health at a South Florida event, highlighting the importance of informed healthcare decisions.
Creative Biolabs Enhances Cell Therapy Research with Advanced iPSC and Macrophage Solutions
Creative Biolabs introduces innovative tools and services for iPSC neural differentiation and macrophage isolation, significantly advancing cell therapy research and disease modeling.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
Quantum Computing: A Revolutionary Leap in Problem-Solving
Quantum computing represents a significant advancement in technology, offering unprecedented capabilities to solve complex problems across various industries.
Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
Experimental mRNA Vaccine Shows Promise in Enhancing Cancer Immunotherapy
Researchers have discovered that an experimental mRNA vaccine could significantly improve the effectiveness of immunotherapy in fighting tumors, marking a potential advancement towards universal cancer vaccines.
Torr Metals Inc. Reports High-Grade Copper Findings at Kolos Project
Torr Metals Inc. announces significant copper findings at its Kolos Copper-Gold Project, signaling potential for substantial mineral exploration and development in British Columbia.
ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborns with HIE
A preclinical study reveals pegtarazimod's ability to significantly reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE), offering hope for a new treatment approach.
Dr. Matt Kaeberlein on Bridging the Gap Between Longevity Research and Clinical Practice
Dr. Matt Kaeberlein discusses the transition from academic research to clinical application in longevity science through Optispan, emphasizing evidence-based health optimization.
CLL Society Honors Innovators in Leukemia and Lymphoma Research
The CLL Society has awarded three researchers for their innovative projects aimed at improving care and outcomes for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, highlighting the importance of integrative medicine, clinical research, and overcoming treatment resistance.
NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.